Business Context and Reporting Period
This Form 8-K filing by Aerpio Pharmaceuticals, Inc. (not Whitehawk Therapeutics, Inc.) was submitted on October 8, 2017. The report details significant executive leadership changes, specifically the appointment of a new Chief Executive Officer and the transition of the former CEO to a different role.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
Material Changes
- Leadership Transition: Stephen Hoffman, M.D., Ph.D., was appointed as Chief Executive Officer, effective December 1, 2017, succeeding Joseph H. Gardner.
- Role Change: Joseph H. Gardner resigned as CEO and transitioned to the role of President and Founder effective immediately.
- Board Composition: Dr. Hoffman is anticipated to be appointed to the Board of Directors as a Class I director. Dr. Gardner agreed to resign from the Board effective December 31, 2018.
Compensation, Outlook, and Risks
Stephen Hoffman (New CEO)
- Base Salary: $470,000 annually.
- Performance Bonus: Targeted at 50% of base salary.
- Equity Grant: Stock option to purchase shares equal to 2% of the Company's outstanding capital stock on a fully-diluted basis. Vesting is 25% on the first anniversary and monthly thereafter.
- Severance: 12 months of base salary plus 12 months of medical benefits and 12 months of accelerated vesting upon termination without cause or for good reason. In the event of a change in control within 15 months, severance increases to 1.5 times the sum of base salary and target bonus.
Joseph Gardner (President and Founder)
- Base Salary: Increased to $410,000 annually.
- Performance Bonus: Increased to 50% of base salary.
- Equity Grant: Stock option to purchase 135,000 shares, vesting in full on July 1, 2018, contingent on continued employment.
- Severance: 12 months of base salary and 12 months of accelerated vesting if employment ends before July 1, 2018 for reasons other than "Cause."
Risks and Contingencies
The Company has entered into an indemnification agreement with Dr. Hoffman, potentially requiring the Company to cover legal expenses, judgments, fines, and settlements arising from his service as an officer. Dr. Hoffman is also subject to non-competition and non-solicitation provisions for one year post-employment.
Investor Verification Checklist
- Verify the exact number of shares underlying Dr. Hoffman's 2% equity grant based on the fully-diluted capital stock count on the grant date.
- Confirm the closing price of the Company's common stock on the OTCQB on the grant date to determine the exercise price for both executives' stock options.
- Review the full text of the employment agreements (Exhibits 10.1 and 10.2) for specific definitions of "Cause," "Good Reason," and "Change in Control."
- Monitor the Company's cash position to ensure it can support the increased executive compensation and potential severance liabilities.